Filtered By:
Source: Annals of Internal Medicine
Condition: Bleeding

This page shows you your search results in order of date. This is page number 3.

Order by Relevance | Date

Total 54 results found since Jan 2013.

Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation : A Population-Based Cohort Study
CONCLUSION: In this comparative effectiveness study using practice-based claims data, patients with valvular AF who were new users of DOACs had lower risks for ischemic stroke or systemic embolism and major bleeding than new users of warfarin. These data may be used to guide risk-benefit discussions regarding anticoagulant choices for patients with valvular AF.PRIMARY FUNDING SOURCE: None.PMID:33780291 | DOI:10.7326/M20-6194
Source: Annals of Internal Medicine - March 29, 2021 Category: Internal Medicine Authors: Ghadeer K Dawwas Eric Dietrich Adam Cuker Geoffrey D Barnes Charles E Leonard James D Lewis Source Type: research

In older patients with AF, low-dose edoxaban reduced stroke or systemic embolism without increasing major bleeding.
Abstract SOURCE CITATION: Okumura K, Akao M, Yoshida T, et al. Low-dose edoxaban in very elderly patients with atrial fibrillation. N Engl J Med. 2020;383:1735-45. 32865374. PMID: 33395333 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - January 5, 2021 Category: Internal Medicine Authors: Steinberg DI Tags: Ann Intern Med Source Type: research

In acute ischemic stroke or TIA, adding ticagrelor to aspirin reduced stroke or death and increased severe bleeding.
Abstract SOURCE CITATION: Johnston SC, Amarenco P, Denison H, et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med. 2020;383:207-17. 32668111. PMID: 33316187 [PubMed - in process]
Source: Annals of Internal Medicine - December 15, 2020 Category: Internal Medicine Authors: Hill MD Tags: Ann Intern Med Source Type: research

Age- and Weight-Adapted Dose of Prasugrel Versus Standard Dose of Ticagrelor in Patients With Acute Coronary Syndromes: Results From a Randomized Trial.
CONCLUSION: In elderly or low-weight patients with ACS, a reduced dose of prasugrel compared with the standard dose of ticagrelor is associated with maintained anti-ischemic efficacy while protecting these patients against the excess risk for bleeding. PRIMARY FUNDING SOURCE: German Center for Cardiovascular Research and Deutsches Herzzentrum München. PMID: 32687741 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - July 20, 2020 Category: Internal Medicine Authors: Menichelli M, Neumann FJ, Ndrepepa G, Mayer K, Wöhrle J, Bernlochner I, Richardt G, Witzenbichler B, Sibbing D, Gewalt S, Angiolillo DJ, Lahu S, Hamm CW, Hapfelmeier A, Trenk D, Laugwitz KL, Schunkert H, Schüpke S, Kastrati A Tags: Ann Intern Med Source Type: research

Dual Versus Triple Therapy for Atrial Fibrillation After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis.
Conclusion: In adults with AF after PCI, dual therapy reduces risk for bleeding compared with triple therapy, whereas its effects on risks for death and ischemic end points are still unclear. Primary Funding Source: None. PMID: 32176890 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - March 16, 2020 Category: Internal Medicine Authors: Khan SU, Osman M, Khan MU, Khan MS, Zhao D, Mamas MA, Savji N, Al-Abdouh A, Hasan RK, Michos ED Tags: Ann Intern Med Source Type: research

Effectiveness and Safety of Apixaban Compared With Rivaroxaban for Patients With Atrial Fibrillation in Routine Practice: A Cohort Study.
Conclusion: In routine care, adults with atrial fibrillation prescribed apixaban had a lower rate of both ischemic stroke or systemic embolism and bleeding compared with those prescribed rivaroxaban. Primary Funding Source: Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital. PMID: 32150751 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - March 9, 2020 Category: Internal Medicine Authors: Fralick M, Colacci M, Schneeweiss S, Huybrechts KF, Lin KJ, Gagne JJ Tags: Ann Intern Med Source Type: research

Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial.
Conclusion: Rivaroxaban did not show noninferiority to dose-adjusted VKAs for thrombotic APS and, in fact, showed a non-statistically significant near doubling of the risk for recurrent thrombosis. Primary Funding Source: Bayer Hispania. PMID: 31610549 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - October 14, 2019 Category: Internal Medicine Authors: Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, Vidal X, Riera-Mestre A, Castro-Salomó A, Cuquet-Pedragosa J, Ortiz-Santamaria V, Mauri-Plana M, Solé C, Cortés-Hernández J Tags: Ann Intern Med Source Type: research

Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease: A Systematic Review and Meta-analysis.
Conclusion: In early-stage CKD, NOACs had a benefit-risk profile superior to that of VKAs. For advanced CKD or ESKD, there was insufficient evidence to establish benefits or harms of VKAs or NOACs. Primary Funding Source: None. (PROSPERO: CRD42017079709). PMID: 31307056 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - July 15, 2019 Category: Internal Medicine Authors: Ha JT, Neuen BL, Cheng LP, Jun M, Toyama T, Gallagher MP, Jardine MJ, Sood MM, Garg AX, Palmer SC, Mark PB, Wheeler DC, Jha V, Freedman B, Johnson DW, Perkovic V, Badve SV Tags: Ann Intern Med Source Type: research

In AF, ABC scores predicted stroke or major bleeding better than CHA2DS2-VASc and HAS-BLED scores, respectively.
PMID: 31207624 [PubMed - in process]
Source: Annals of Internal Medicine - June 17, 2019 Category: Internal Medicine Authors: Kearon C Tags: Ann Intern Med Source Type: research

Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review.
Conclusion: The available direct-acting oral anticoagulants (DOACs) are at least as effective and safe as warfarin for patients with nonvalvular AF. The DOACs had similar benefits across several patient subgroups and seemed safe and efficacious for a wide range of patients with nonvalvular AF. Primary Funding Source: Patient-Centered Outcomes Research Institute. (PROSPERO: CRD42017069999). PMID: 30383133 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - October 30, 2018 Category: Internal Medicine Authors: Lowenstern A, Al-Khatib SM, Sharan L, Chatterjee R, LaPointe NMA, Shah B, Borre ED, Raitz G, Goode A, Yapa R, Davis JK, Lallinger K, Schmidt R, Kosinski AS, Sanders GD Tags: Ann Intern Med Source Type: research

In embolic stroke of undetermined source, rivaroxaban vs aspirin did not reduce recurrence and increased bleeding.
PMID: 30242405 [PubMed - in process]
Source: Annals of Internal Medicine - September 18, 2018 Category: Internal Medicine Authors: Frieden RW Tags: Ann Intern Med Source Type: research

Device Closure Versus Medical Therapy Alone for Patent Foramen Ovale in Patients With Cryptogenic Stroke: A Systematic Review and Meta-analysis.
Conclusion: In patients with PFO and cryptogenic stroke, transcatheter device closure decreases risk for recurrent stroke compared with medical therapy alone. Because recurrent stroke rates are low even with medical therapy alone and PFO closure might affect AF risk, shared decision making is crucial for this treatment. Primary Funding Source: None. PMID: 29310136 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - January 9, 2018 Category: Internal Medicine Authors: Shah R, Nayyar M, Jovin IS, Rashid A, Bondy BR, Fan TM, Flaherty MP, Rao SV Tags: Ann Intern Med Source Type: research

Should This Patient Receive Aspirin?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
Discussion From Beth Israel Deaconess Medical Center. Ann Intern Med. 2017 Dec 05;167(11):786-793 Authors: Burns RB, Graham K, Sawhney MS, Reynolds EE Abstract Aspirin exerts antiplatelet effects through irreversible inhibition of cyclooxygenase-1, whereas its anticancer effects may be due to inhibition of cyclooxygenase-2 and other pathways. In 2009, the U.S. Preventive Services Task Force endorsed aspirin for primary prevention of cardiovascular disease. However, aspirin's role in cancer prevention is still emerging, and no groups currently recommend its use for this purpose. To help physicians bala...
Source: Annals of Internal Medicine - December 5, 2017 Category: Internal Medicine Authors: Burns RB, Graham K, Sawhney MS, Reynolds EE Tags: Ann Intern Med Source Type: research